Cargando…
Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis
Tripterygium wilfordii Hook F (TwHF) is one of the most commonly used and effective traditional Chinese herbal medicines against rheumatoid arthritis (RA). Both Tripterygium Glycoside Tablets (TGT) and Tripterygium wilfordii Tablets (TWT) are the representative TwHF-based agents enrolled into the 20...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845140/ https://www.ncbi.nlm.nih.gov/pubmed/33519474 http://dx.doi.org/10.3389/fphar.2020.608703 |
_version_ | 1783644496381083648 |
---|---|
author | Lin, Na Zhang, Yan-Qiong Jiang, Quan Liu, Wei Liu, Jian Huang, Qing-Chun Wu, Kuan-Yu Tu, Sheng-Hao Zhou, Zu-Shan Chen, Wei-Heng Li, Xiao-Xia Ding, Ying Fang, Yong-Fei Liu, Jian-Ping Li, Zhen-Bin He, Dong-Yi Chen, Yao-Long Lou, Yu-Qian Tao, Qing-Wen Wang, Qing-Wen Jin, Ying-Hui Liao, Xing Li, Tai-Xian Wang, Xiao-Yue |
author_facet | Lin, Na Zhang, Yan-Qiong Jiang, Quan Liu, Wei Liu, Jian Huang, Qing-Chun Wu, Kuan-Yu Tu, Sheng-Hao Zhou, Zu-Shan Chen, Wei-Heng Li, Xiao-Xia Ding, Ying Fang, Yong-Fei Liu, Jian-Ping Li, Zhen-Bin He, Dong-Yi Chen, Yao-Long Lou, Yu-Qian Tao, Qing-Wen Wang, Qing-Wen Jin, Ying-Hui Liao, Xing Li, Tai-Xian Wang, Xiao-Yue |
author_sort | Lin, Na |
collection | PubMed |
description | Tripterygium wilfordii Hook F (TwHF) is one of the most commonly used and effective traditional Chinese herbal medicines against rheumatoid arthritis (RA). Both Tripterygium Glycoside Tablets (TGT) and Tripterygium wilfordii Tablets (TWT) are the representative TwHF-based agents enrolled into the 2019 edition of Medicine Catalog for National Basic Medical Insurance, Injury Insurance, and Maternity Insurance. However, individual differences in TGT/TWT response across patients usually exist in the process of treating RA, implying that the clinical application of the two agents may not be standardized leading to the ineffective treatment and the risk of side effects. Growing evidence show that the bioactive constituents of TwHF may often have toxicity, the package insert of TGT and TWT may not be described in detail, and the therapeutic windows of the two agents are narrow. Thus, it is an urgent task to develop a standardized clinical practice guideline for TGT and TWT in the treatment of RA. In the current study, a group of clinical experts of traditional Chinese medicine and Western medicine in the research field of rheumatism diseases, pharmacists, and methodologists of evidence-based medicine were invited to select the clinical questions, to determine the levels of the evidence and the strength of the recommendations, and to develop the recommendations and good practice points. The guideline is formed based on the combination of clinical research evidence and expert experience (evidence-based, consensus, supplemented by experience). The clinical problems which are supported by clinical evidence may form recommendations, and the clinical problems without clinical evidence may form experts’ suggestions. Both recommendations and experts' suggestions in this guideline summarized the clinical indications, usage, dosage, combined medication, and safety of TGT and TWT against RA systematically and comprehensively, which may offer a professional guidance in the context of the clinical application of the two TwHF-based agents. |
format | Online Article Text |
id | pubmed-7845140 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78451402021-01-30 Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis Lin, Na Zhang, Yan-Qiong Jiang, Quan Liu, Wei Liu, Jian Huang, Qing-Chun Wu, Kuan-Yu Tu, Sheng-Hao Zhou, Zu-Shan Chen, Wei-Heng Li, Xiao-Xia Ding, Ying Fang, Yong-Fei Liu, Jian-Ping Li, Zhen-Bin He, Dong-Yi Chen, Yao-Long Lou, Yu-Qian Tao, Qing-Wen Wang, Qing-Wen Jin, Ying-Hui Liao, Xing Li, Tai-Xian Wang, Xiao-Yue Front Pharmacol Pharmacology Tripterygium wilfordii Hook F (TwHF) is one of the most commonly used and effective traditional Chinese herbal medicines against rheumatoid arthritis (RA). Both Tripterygium Glycoside Tablets (TGT) and Tripterygium wilfordii Tablets (TWT) are the representative TwHF-based agents enrolled into the 2019 edition of Medicine Catalog for National Basic Medical Insurance, Injury Insurance, and Maternity Insurance. However, individual differences in TGT/TWT response across patients usually exist in the process of treating RA, implying that the clinical application of the two agents may not be standardized leading to the ineffective treatment and the risk of side effects. Growing evidence show that the bioactive constituents of TwHF may often have toxicity, the package insert of TGT and TWT may not be described in detail, and the therapeutic windows of the two agents are narrow. Thus, it is an urgent task to develop a standardized clinical practice guideline for TGT and TWT in the treatment of RA. In the current study, a group of clinical experts of traditional Chinese medicine and Western medicine in the research field of rheumatism diseases, pharmacists, and methodologists of evidence-based medicine were invited to select the clinical questions, to determine the levels of the evidence and the strength of the recommendations, and to develop the recommendations and good practice points. The guideline is formed based on the combination of clinical research evidence and expert experience (evidence-based, consensus, supplemented by experience). The clinical problems which are supported by clinical evidence may form recommendations, and the clinical problems without clinical evidence may form experts’ suggestions. Both recommendations and experts' suggestions in this guideline summarized the clinical indications, usage, dosage, combined medication, and safety of TGT and TWT against RA systematically and comprehensively, which may offer a professional guidance in the context of the clinical application of the two TwHF-based agents. Frontiers Media S.A. 2021-01-14 /pmc/articles/PMC7845140/ /pubmed/33519474 http://dx.doi.org/10.3389/fphar.2020.608703 Text en Copyright © 2021 Lin, Zhang, Jiang, Liu, Liu, Huang, Wu, Tu, Zhou, Chen, Li, Ding, Fang, Liu, Li, He, Chen, Lou, Tao, Wang, Jin, Liao, Li and Wang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (http://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Lin, Na Zhang, Yan-Qiong Jiang, Quan Liu, Wei Liu, Jian Huang, Qing-Chun Wu, Kuan-Yu Tu, Sheng-Hao Zhou, Zu-Shan Chen, Wei-Heng Li, Xiao-Xia Ding, Ying Fang, Yong-Fei Liu, Jian-Ping Li, Zhen-Bin He, Dong-Yi Chen, Yao-Long Lou, Yu-Qian Tao, Qing-Wen Wang, Qing-Wen Jin, Ying-Hui Liao, Xing Li, Tai-Xian Wang, Xiao-Yue Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis |
title | Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis |
title_full | Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis |
title_fullStr | Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis |
title_full_unstemmed | Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis |
title_short | Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis |
title_sort | clinical practice guideline for tripterygium glycosides/tripterygium wilfordii tablets in the treatment of rheumatoid arthritis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845140/ https://www.ncbi.nlm.nih.gov/pubmed/33519474 http://dx.doi.org/10.3389/fphar.2020.608703 |
work_keys_str_mv | AT linna clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis AT zhangyanqiong clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis AT jiangquan clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis AT liuwei clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis AT liujian clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis AT huangqingchun clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis AT wukuanyu clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis AT tushenghao clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis AT zhouzushan clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis AT chenweiheng clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis AT lixiaoxia clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis AT dingying clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis AT fangyongfei clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis AT liujianping clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis AT lizhenbin clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis AT hedongyi clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis AT chenyaolong clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis AT louyuqian clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis AT taoqingwen clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis AT wangqingwen clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis AT jinyinghui clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis AT liaoxing clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis AT litaixian clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis AT wangxiaoyue clinicalpracticeguidelinefortripterygiumglycosidestripterygiumwilfordiitabletsinthetreatmentofrheumatoidarthritis |